Skip to content

Clinical trials

Phase 1/2 Breast Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Breast Neoplasms Phase: Phase 1/2 Country / region: United States Clear all

398 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20009
20017
20027
20036
200410
200510
200614
200717
200815
200923
201015
20115
20127
20136
201417
201520
201617
201724
201816
201918
202014
202116
202223
202325
202412
202514
202611

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed187
Terminated82
Recruiting53
Active, not recruiting40
Withdrawn16
Unknown status14
Not yet recruiting4
Suspended2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)22
Memorial Sloan Kettering Cancer Center12
Pfizer11
Novartis Pharmaceuticals10
M.D. Anderson Cancer Center9
University of Washington8
NYU Langone Health7
AstraZeneca6
H. Lee Moffitt Cancer Center and Research Institute6
Puma Biotechnology, Inc.5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms398
Ovarian Neoplasms58
Carcinoma, Non-Small-Cell Lung42
Neoplasm Metastasis34
Triple Negative Breast Neoplasms34
Pancreatic Neoplasms32
Colorectal Neoplasms30
Neoplasms30
Breast Neoplasms, Male29
Endometrial Neoplasms28

Trials

Showing 1 to 25 of 398. Each trial links to its page on Pharma Observatory.

298 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.